Recent progress in the discovery and development of cyclin-dependent kinase inhibitors

Expert Opinion on Investigational Drugs

Volumn 14, Issue 4, 2005, Pages 457-477

  Fischer, Peter M ^a   Gianella Borradori, Athos ^a  

^a CYCLACEL LTD   (United Kingdom)

Author keywords

7 hydroxystaurosporine; Alvocidib; Aminothiazole; Bisindolylmaleimide; BMS 387032; CDK inhibitor; CYC202; E7070; Flavopiridol; HIV; Indisulam; Ro 31 7453; Roscovitine; Seliciclib; UCN 01

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 7 HYDROXYSTAUROSPORINE; ANTIDIARRHEAL AGENT; AZD 5438; BCR ABL PROTEIN; CAPECITABINE; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; CYTARABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE; FLAVOPIRIDOL; FLUDARABINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; GPC 286199; IMATINIB; INDIRUBIN; INDISULAM; IRINOTECAN; JNJ 7706621; METHOTREXATE; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; ON 01910; OXALIPLATIN; PACLITAXEL; PD 0332991; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN P53; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITUXIMAB; RNA POLYMERASE II; ROSCOVITINE; SULFONE DERIVATIVE; TOPOTECAN; TRASTUZUMAB; UNCLASSIFIED DRUG; WARFARIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIVIRAL ACTIVITY; APOPTOSIS; B CELL LEUKEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG ELIMINATION; DRUG ERUPTION; DRUG INDICATION; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME REGULATION; FATIGUE; GENETIC TRANSCRIPTION; GLOMERULONEPHRITIS; GLOMERULOPATHY; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HYPERGLYCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY CANCER; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; MELANOMA; META ANALYSIS; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEPHROLOGY; ONCOLOGY; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS; TRANSCRIPTION REGULATION; TREATMENT OUTCOME; VIROLOGY;

AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; CLINICAL TRIALS; CYCLIN-DEPENDENT KINASES; DRUG RESISTANCE, NEOPLASM; FEMALE; FLAVONOIDS; GLOMERULONEPHRITIS; HEMATOLOGIC NEOPLASMS; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; PIPERIDINES; PROTEIN KINASE INHIBITORS; PURINES; TRANSCRIPTION, GENETIC;

EID: 19044371037     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.14.4.457     Document Type: Review

References (228)

1. FISCHER PM, GIANELLA-BORRADORI A: CDK inhibitors in clinical development for the treatment of cancer. Expert Opin. Investig. Drugs (2003) 12:955-970.
2. FISCHER PM, ENDICOTT J, MEIJER L: Cyclin-dependent kinase inhibitors. Progr. Cell Cycle Res. (2003) 5:235-248.
3. KONG N, FOTOUHI N, WOVKULICH PM et al.: Cell cycle inhibitors for the treatment of cancer. Drugs of the Future (2003) 28:881-896.
4. SENDEROWICZ AM: Small-molecule cyclin-dependent kinase modulators. Oncogene (2003) 22:6609-6620.
5. FISCHER PM: The use of CDK inhibitors in oncology: a pharmaceutical perspective. Cell Cycle (2004) 3:742-746.
6. TREMBLEY JH, LOYER P, HU D et al.: Cyclin dependent kinase 11 in RNA transcription and splicing. Progr. Nucleic Acid Res. Mol. Biol. (2004) 77:263-288.
7. KNOCKAERT M, GREENGARD P, MEIJER L: Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. (2002) 23:417-425.
8. MARZO N, MORA C, FABREGAT ME et al.: Pancreatic islets from cyclin-dependent kinase 4/R24C (Cdk4) knockin mice have significantly increased β cell mass and are physiologically functional, indicating that Cdk4 is a potential target for pancreatic b cell mass regeneration in type 1 diabetes. Diabetologia (2004) 47:686-694.
9. KOZAR K, CIEMERYCH MA, REBEL VI et al.: Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 118:477-491.
10. MALUMBRES M, SOTILLO R, SANTAMARIA D et al.: Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 118:493-504.
11. ORTEGA S, MALUMBRES M, BARBACID M: Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim. Biophys. Acta (2002) 1602:73-87.
12. ORTEGA S, PRIETO I, ODAJIMA J et al.: Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat. Genet. (2003) 35:25-31.
13. GENG Y, YU Q, SICINSKA E et al.: Cyclin E ablation in the mouse. Cell (2003) 114:431-443.
14. BERTHET C, ALEEM E, COPPOLA V et al.: Cdk2 knockout mice are viable. Curr. Biol. (2003) 13:1775-1785.
15. BLAGOSKLONNY MV: Do cells need CDK2 and. Bcr-Abl? Cell Death Differ. (2004) 11:249-251.
16. GRIM JE, CLURMAN BE: Cycling without CDK2? Trends Cell Biol. (2003) 13:396-399.
17. ZHU Y, ALVAREZ C, DOLL R et al.: Intra-S-phase checkpoint activation by direct CDK2 inhibition. Mol. Cell. Biol. (2004) 24:6268-6277.
18. HARWELL RM, MULL BB, PORTER DC et al.: Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J. Biol. Chem. (2004) 279:12695-12705.
19. ERLANDSSON F, WAHLBY C, EKHOLM-REED S et al.: Abnormal expression pattern of cyclin E in tumour cells. Int. J. Cancer (2003) 104:369-375.
20. LI K, LIN S-Y, BRUNICARDI FC et al.: Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res. (2003) 63:3593-3597.
21. TETSU O, McCORMICK F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell (2003) 3:233-245.
22. JIANG J, MATRANGA CB, CAI D et al.: Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Cancer Res. (2003) 63:7410-7422.
23. LITZ J, CARLSON P, WARSHAMANA-GREENE GS et al.: Flavopiridol potently induces small cell lung cancer apoptosis during S phase in a manner that involves early mitochondrial dysfunction. Clin. Cancer Res. (2003) 9:4586-4594.
24. RIBAS J, BOIX J: Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs. Exp. Cell Res. (2004) 295:9-24.
25. CHEN W, LEE J, CHO SY et al.: Proteasome-mediated destruction of the cyclin a/cyclin-dependent kinase 2 complex suppresses tumor cell growth in vitro and in vivo. Cancer Res. (2004) 64:3949-3957.
26. VAN DEN HEUVEL S, HARLOW E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science (1993) 262:2050-2054.
27. YUAN J, YAN R, KRAMER A et al.: Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 23:5843-5852.
28. SEONG Y-S, MIN C, LI L et al.: Characterization of a novel cyclin-dependent kinase 1 inhibitor, BMI-1026. Cancer Res. (2003) 63:7384-7391.
29. HAM Y-M, CHOI K-J, SONG S-Y et al.: Xylocydine, a novel inhibitor of cyclin-dependent kinases, prevents the tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic cell death of SK-HEP-1 cells. J. Pharmacol. Exp. Ther. (2004) 308:814-819.
30. SONI DV, JACOBBERGER JW: Inhibition of Cdk1 by alsterpaullone and thioflavopiridol correlates with increased transit time from mid G(2) through prophase. Cell Cycle (2004) 3:349-357.
31. LIN PS, DUBOIS M-F, DAHMUS ME: TFIIF-associating carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II. J. Biol. Chem. (2002) 277:45949-45956.
32. OELGESCHLAGER T: Regulation of RNA polymerase II activity by CTD phosphorylation and cell cycle control. J. Cell. Physiol. (2002) 190:160-169.
33. KOBOR MS, GREENBLATT J: Regulation of transcription elongation by phosphorylation. Biochim. Biophys. Acta (2002) 13:261-275.
34. DENG L, AMMOSOVA T, PUMFERY A et al.: HIV-1 Tat interaction with RNA polymerase II C-terminal domain (CTD) and a dynamic association with CDK2 induce CTD phosphorylation and transcription from HIV-1 promoter. J. Biol. Chem. (2002) 277:33922-33929.
35. PINHERO R, LIAW P, BERTENS K et al.: Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II. Eur. J. Biochem. (2004) 271:1004-1014.
36. LJUNGMAN M, LANE DP: Opinion: transcription - guarding the genome by sensing DNA damage. Nat. Rev. Cancer (2004) 4:727-737.
37. KOUMENIS C, GIACCIA A: Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. Mol. Cell. Biol. (1997) 17:7306-7316.
38. TE POELE RH, OKOROKOV AL, JOEL SP: RNA synthesis block by 5,6--dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells. Oncogene (1999) 18:5765-5772.
39. CHANG T-C, TSAI L-C, HUNG M-W et al.: Effects of transcription and translation inhibitors on a human gastric carcinoma cell line. Potential role of Bcl-XS in apoptosis triggered by these inhibitors. Biochem. Pharmacol. (1997) 53:969-977.
40. WIELAND T, FAULSTICH H: Fifty years of amanitin. Experientia (1991) 47:1186-1193.
41. ZANDOMENI R, MITTLEMAN B, BUNICK D et al.: Mechanism of action of dichloro-β-D-ribofuranosylbenzimidazole: effect on in vitro transcription. Proc. Natl. Acad. Sci. USA (1982) 79:3167-3170.
42. SHIMA D, YUGAMI M, TATSUNO M et al.: Mechanism of H-8 inhibition of cyclin-dependent kinase 9: study using inhibitor-immobilized matrices. Genes To Cells (2003) 8:215-223.
43. PEPPER C, THOMAS A, HOY T et al.: Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function, Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol. Cell Cycle (2003) 2:53-58.
44. SCHEER U, HUGLE B, HAZAN R et al.: Drug-induced dispersal of transcribed rRNA genes and transcriptional products: immunolocalization and silver staining of different nucleolar components in rat cells treated with 5,6-dichloro-β-D-ribofuranosylbenzimidazole. J. Cell. Biol. (1984) 99:672-679.
45. HAAF T, WARD DC: Inhibition of RNA polymerase II transcription causes chromatin decondensation, loss of nucleolar structure, and dispersion of chromosomal domains. Exp. Cell Res. (1996) 224:163-173.
46. DAVID-PFEUTY T: Potent inhibitors of cyclin-dependent kinase 2 induce nuclear accumulation of wild-type p53 and nucleolar fragmentation in human untransformed and tumor-derived cells. Oncogene (1999) 18:7409-7422.
47. LJUNGMAN M, PAULSEN MT: The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Set 15 and Lys382. Mol. Pharmacol. (2001) 60:785-789.
48. WOJCIECHOWSKI J, HORKY M, GUEORGUIEVA M et al.: Rapid onset of nucleolar disintegration preceding cell cycle arrest in roscovitine-induced apoptosis of human MCF-7 breast cancer cells. Int. J. Cancer (2003) 106:486-495.
49. LU W, CHEN L, PENG Y et al.: Activation of p53 by roscovitine-mediated suppression of MDM2 expression. Oncogene (2001) 20:3206-3216.
50. LAM LT, PICKERAL OK, PENG AC et al.: Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genomebiology.Com (2001) 2:1465-6914.
51. WITTMANN S, BALI P, DONAPATY S et al.: Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. (2003) 63:93-99.
52. ALVI AJ, GIANELLA-BORRADORI A, LANE DP et al.: A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-cell chronic lymphocytic leukaemia by down-regulation of genes involved in transcription regulation and repair. Blood (2003) 102(11):Abstract 1587.
53. MacCALLUM DE, MELVILLE J, WATT K et al.: CYC202 (R-Roscovitine) induces apoptosis in multiple myeloma cells by down regulation of Mcl-1. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 823.
54. HAHNTOW IN, SCHNELLER F, OELSNER M et al.: Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia (2004) 18:747-755.
55. VALENTINI A, LAMBERTINI C, RINALDI A et al.: Activity of cyclin-dependent protein kinase (CDK)-inhibitor CYC202 (R-roscovitine) in mantle cell lymphoma. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 827.
56. MA Y, CRESS WD, HAURA EB: Flavopiridol-induced apoptosis is mediated through up-regulation of E2F1 and repression of Mcl-1. Mol. Cancer Ther. (2003) 2:73-81.
57. KIM EH, KIM SU, SHIN DY et al.: Roscovitine sensitizes glioma cells to TRAIL-mediated apoptosis by downregulation of survivin and XIAP. Oncogene (2004) 23:446-456.
58. LEE EG, BOONE DL, CHAI S et al.: Failure to regulate TNF-induced NF-κB and cell death responses in A20-deficient mice. Science (2000) 289:2350-2354.
59. MOISAN A, LAROCHELLE C, GUILLEMETTE B et al.: BRCA1 can modulate RNA polymerase II carboxy-terminal domain phosphorylation levels. Mol. Cell. Biol. (2004) 24:6947-6956.
60. KITADA S, REED JC: MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J. Natl. Cancer Inst. (2004) 96:642-643.
61. MICHELS J, O'NEILL JW, DALLMAN CL et al.: Mcl-1 is required for Akata6 B-lymphoma cell survival and is converted to a cell death molecule by efficient caspase-mediated cleavage. Oncogene (2004) 23:4818-4827.
62. KOZOPAS KM, YANG T, BUCHAN HL et al.: MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc. Natl. Acad. Sci. USA (1993) 90:3516-3520.
63. CRAIG RW: MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis. Leukemia (2002) 16:444-454.
64. IGLESIAS-SERRET D, PIQUE M, GIL J et al.: Transcriptional and translational control of Mcl-1 during apoptosis. Arch. Biochem. Biophys. (2003) 417:141-152.
65. SEMENOV I, AKYUZ C, ROGINSKAYA V et al.: Growth inhibition and apoptosis of myeloma cells by the CDK inhibitor flavopiridol. Leukemia Res. (2002) 26:271-280.
66. GOJO I, ZHANG B, FENTON RG: The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1. Clin. Cancer Res. (2002) 8:3527-3538.
67. HIDDEMANN W, DREYLING M: Mantle cell lymphoma: therapeutic strategies are different from CLL. Curr. Treat. Options Oncol. (2003) 4:219-226.
68. KARP JE, DONEHOWER RC, ENTERLINE JP et al.: In vivo cell growth and pharmacologic determinants of clinical response in acute myelogenous leukemia. Blood (1989) 73:24-30.
69. KARP JE, BURKE PJ: Growth response of residual leukemia after initial drug therapy. Cancer Res. (1986) 46:4205-4207.
70. KARP JE, ROSS DD, YANG W et al.: Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a Phase I clinical trial. Clin. Cancer Res. (2003) 9:307-315.
71. CAPDEVILLE R, BUCHDUNGER E, ZIMMERMANN J et al.: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Disc. (2002) 1:493-502.
72. YOSHIDA C, MELO JV: Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol. (2004) 79:420-433.
73. YU C, KRYSTAL G, DENT P et al.: Flavopiridol potentiates STI571-induced mitochondrial damage and apoptosis in BCR-ABL-positive human leukemia cells. Clin. Cancer Res. (2002) 8:2976-2984.
74. DAI Y, RAHMANI M, PEI X-Y et al.: Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood (2004) 104:509-518.
75. GRANT S, ROBERTS JOHN D: The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist. Updat. (2003) 6:15-26.
76. ABAL M, BRAS-GONCALVES R, JUDDE J-G et al.: Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line. Oncogene (2004) 23:1737-1744.
77. FRESNO VARA JA, CASADO E, DE CASTRO J et al.: PI3K/Akt signalling pathway and cancer. Cancer Treat. Rev. (2004) 30:193-204.
78. YU C, RAHMANI M, DAI Y et al.: The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. (2003) 63:1822-1833.9
79. WITTERS LM, MYERS A, LIPTON A: Combining flavopiridol with various signal transduction inhibitors. Oncol. Rep. (2004) 11:693-698.
80. YANG C, IONESCU-TIBA V, BURNS K et al.: The role of the cyclin D1-dependent kinases in ErbB2 -mediated breast cancer. Am. J. Pathol. (2004) 164:1031-1038.
81. WU K, WANG C, D'AMICO M et al.: Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol. Cancer Ther. (2002) 1:695-706.
82. NAHTAR R, IGLEHART JD, KEMPKES B et al.: Rate-limiting effects of Cyclin D1 in transformation by ErbB2 predicts synergy between herceptin and flavopiridol. Cancer Res. (2002) 62:2267-2271.
83. NAHTA R, TRENT S, YANG C et al.: Epidermal growth factor receptor expression is a candidate target of the synergistic combination of trastuzumab and flavopiridol in breast cancer. Cancer Res. (2003) 63:3626-3631.
84. SCHLESSINGER J: Cell signaling by receptor tyrosine kinases. Cell (2000) 103:211-225.
85. NAHTA R, TAKAHASHI T, UENO NT et al.: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res. (2004) 64:3981-3986.
86. BIBLE KC, KAUFMANN SH: Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res. (1997) 57:3375-3380.
87. MOTWANI M, DELOHERY TM, SCHWARTZ GK: Sequential dependent enhancement of caspase activation and apoptosis by flavopiridol on paclitaxel-treated human gastric and breast cancer cells. Clin. Cancer Res. (1999) 5:1876-1883.
88. MACK PC, MAHAFFEY CM, GUMERLOCK PH et al.: Enhancing the anticancer activity of paclitaxel through cyclin-dependent kinase inhibition. Proc. Am. Assoc. Cancer Res. (2004) 45:(Abstract 5434).
89. O'CONNOR DS, WALL NR, PORTER ACG et al.: A p34(cdc2) survival checkpoint in cancer. Cancer Cell (2002) 2:43-54.
90. WALL NR, O'CONNOR DS, PLESCIA J et al.: Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. Cancer Res. (2003) 63:230-235.
91. MATRANGA CB, SHAPIRO GI: Selective sensitization of transformed cells to flavopiridol-induced apoptosis following recruitment to S-phase. Cancer Res. (2002) 62:1707-1717.
92. JUNG CP, MOTWANI MV, SCHWARTZ GK: Flavopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with down-regulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res. (2001) 7:2527-2536.
93. KREK W, XU G, LIVINGSTON DM: Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell (1995) 83:1149-1158.
94. CHEN Y-NP, SHARMA SK, RAMSEY TM et al.: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists. Proc. Natl. Acad. Sci. USA (1999) 96:4325-4329.
95. PEEPER DS, KEBLUSEK P, HELIN K et al.: Phosphorylation of a specific Cdk site in E2F1 affects its electrophoretic mobility and promotes pRB-binding in vitro. Oncogene (1995) 10:39-48.
96. KITAGAWA M, HIGASHI H, SUZUKI-TAKAHASHI I et al.: Phosphorylation of E2F1 by cyclin A-cdk2. Oncogene (1995) 10:229-236.
97. VANDEL L, KOUZARIDES T: Residues phosphorylated by TFIIH are required for E2F1 degradation during S-phase. EMB0 J. (1999) 18:4280-4291.
98. BERGMAN AM, PINEDO HM, PETERS GJ: Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist. Updat. (2002) 5:19-33.
99. SOMERVILLE L, CORY JG: Enhanced roscovitine-induced apoptosis is mediated by a caspase-3-like activity in deoxyadenosine-resistant mouse leukemia L1210 cells. Anti-Cancer Res. (2000) 20:3347-3355.
100. MEIJER L, RAYMOND E: Roscovitine and other purities as kinase inhibitors. From starfish oocytes to clinical trials. Acc. Chem. Res. (2003) 36:417-425.
101. DE LA MOTTE S, GLANELLA-BORRADORI A: Pharmacokinetic model of R-roscovitine and its metabolite in healthy male subjects. Intl. J. Clin. Pharmacol. Ther. (2004) 42:232-239.
102. WHITE JD, CASSIDY J, TWELVES C et al.: A Phase I trial of the oral cyclin dependent kinase inhibitor CYC202 in patients with advanced malignancy. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 3042.
103. PIERGA J-Y, FAIVRE S, VERA K et al.: A Phase I and pharmacokinetic (PK) trial of CYC202, a novel oral cyclin-dependent kinase (CDK) inhibitor, in patients (pts) with advanced solid tumors. Proc. Amer. Soc. Clin. Oncol. (2003) 22:210 (Abstract 840).
104. GREEN S, MACCALLUM DE, FLEMING IN et al.: The mode of action of CYC202 (Rroscovitine) a cyclin dependent kinase inhibitor currently in Phase II clinical trials. Eur. J. Cancer (2004) 2(Suppl. 8):126.
105. FIEBIG H-H, MAIER A, METZ T et al.: Schedule dependency of combining CYC202 (R-roscovitine), a cyclin-dependent kinase inhibitor, with docetaxel in human tumor xenografts in vivo. Clin. Cancer Res. (2003) 9(Suppl. 16):(Abstract C81).
106. GREEN SR, FRAME S, WATT K et al.: Identification of clinically relevant pharmacodynamic biomarkers in patients treated with the CDK inhibitor CYC202 (R-roscovitine). Eur. J. Cancer (2004) 2(Suppl. 8):129.
107. FILIPSKI E, FILIPSKI M, GEORGSSON H et al.: Cyclin-dependent kinase (CDK) inhibitor CYC202 (Rroscovitine) induces clock gene mPer2 mRNA expression rhythm in tumor: relevance for antitumor efficacy. Eur. J. Cancer (2004) 2(Suppl. 8):126.
108. NEWCOMB EW: Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anti Cancer Drugs (2004) 15:4011-419.
109. SHAPIRO GI: Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin. Cancer Res. (2004) 10:4270s-4275s.
110. SEDLACEK HH: Mechanism of action of flavopiridol. Crit. Rev. Oncol. Hematol. (2001) 38:139-170.
111. RUDEK MA, BAUER KS, JR., LUSH RM III et al.: Clinical pharmacology of flavopiridol following a 72-hour continuous infusion. Annals Pharmacother. (2003) 37:1369-1374.
112. AKLILU M, KINDLER HL, DONEHOWER RC et al.: Phase II study of flavopiridol in patients with advanced colorectal cancer. Annals Oncol. (2003) 14:1270-1273.
113. KING DM, LARA P, GANDARA DR et al.: A Phase II trial of flavopiridol in patients with metastatic androgen independent prostate cancer. Proc. Am. Soc. Clin. Oncol. (2003) 22:432 (Abstract 1736).
114. KOUROUKIS CT, BELCH A, CRUMP M et al.: Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a Phase II study of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21:1740-1745.
115. PATEL V, SENDEROWICZ AM, PINTO D Jr et al.: Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Invest. (1998) 102:1674-1681.
116. ARGUELLO F, ALEXANDER M, STERRY JA et al.: Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood (1998) 91:2482-2490.
117. GRIES J-M, BOND J, RODRIGUES L et al.: Phase I study of flavopiridol 24 hour infusion monotherapy in solid tumors (HMR1275/1002). Proc. Am. Soc. Clin. Oncol. (2003) 22:141 (Abstract 564).
118. ZHAI S, SAUSVILLE EA, SENDEROWICZ AM et al.: Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms. Anti Cancer Drugs (2003) 14:125-135.
119. TAN AR, HEADLEE D, MESSMANN R et al.: Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms. J. Clin. Oncol. (2002) 20:4074-4082.
120. VAN VELDHUIZEN PJ, FAULKNER JR, LARA PN et al.: A Phase II study of flavopiridol (Flavo) in patients (pts) with advanced renal cell cancer: Results of Southwest Oncology Group trial S0109. Proc. Am. Soc. Clin. Oncol. (2003) 22:387 (Abstract 1553).
121. BYRD JC, LIN TS, DALTON JT et al.: Flavopiridol administered as a pharmacologically-derived schedule demonstrates marked clinical activity in refractory, genetically high risk, chronic lymphocytic leukemia (CLL). Blood (2004) 104(11):Abstract 341.
122. LIN TS, DALTON JT, WU D et al.: Flavopiridol given as a 30-min intravenous (IV) bolus followed by 4-hr continuous IV infusion (CIVI) results in clinical activity and tumor lysis in refractory chronic lymphocytic leukemia (CLL). J. Clin. Oncol., ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(Suppl. 14S):Abstract 6564.
123. YEE KWL, O'BRIEN SM, GILES FJ: An update on the management of chronic lymphocytic leukaemia. Expert Opin. Pharmacother. (2004) 5:1535-1554.
124. WATTEL E, PREUDHOMME C, HECQUET B et al.: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood (1994) 84:3148-3157.
125. SHAH MA, KORTMANSKY J, GONEN M et al.: Mature results of a Phase I study of irinotecan (CPT) and flavopiridol (F): A clinically and biologically active regimen. Proc. Am. Soc. Clin. Oncol. (2003) 22:262 (Abstract 1051).
126. MOTWANI M, JUNG C, STROTNAK FM et al.: Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct 116 colon cancer monolayers and xenografts. Clin. Cancer Res. (2001) 7:4209-4219.
127. MOTWANI M, SIROTNAK EM, SHE Y et al.: DRG1, a novel target for modulating sensitivity to CPT-11 in colon cancer cells. Cancer Res. (2002) 62:3950-3955.
128. GOFFIN J, APPLEMAN L, RYANA D et al.: A Phase I trial of gemcitabine followed by flavopiridol in patients with solid tumors. Lung Cancer (2003) 41 (Suppl. 2):S179-S181 (Abstract P-348).
129. WECKBECKER G: Biochemical pharmacology and analysis of fluoropyrimidines alone and in combination with modulators. Pharmacol. Ther. (1991) 50:367-424.
130. BIBLE KC, LENSING JL, NELSON SA et al.: A Phase I trial of flavopiridol combined with 5-fluorouracil (5-FU) and leucovorin (CF) in patients with advanced malignancies. Proc. Am. Soc. Clin. Oncol. (2003) 22:218 (Abstract 872).
131. TAN AR, YANG X, BERMAN A et al.: Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with netastatic breast cancer. Clin. Cancer Res. (2004) 10:5038-5047.
132. PATEL B, EL-RAYES BF, GADGEEL SM et al.: A Phase I study of flavopiridol and docetaxel. Proc. Am. Soc. Clin. Oncol. (2003) 22:233 (Abstract 932).
133. KASIMIS B, ROCHA-LIMA C, COGSWELL J et al.: Phase I study evaluating 1-hour flavopiridol (HMR1275) in combination with docetaxel (D) in previously treated non-small cell lung cancer (NSCLC) patient (pts)(HMR1275B/1008). Proc. Am. Soc. Clin. Oncol. (2003) 22:669 (Abstract 2689).
134. RATHKOPF D, FORNIER M, SHAH M et al.: A Phase I dose finding study of weekly, sequential docetaxel (Doc) followed by flavopiridol (F) in patients with advanced solid tumors. J. Clin. Oncol., ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22(Suppl. 14S):Abstract 3072.
135. AKINAGA S, SUGIYAMA K, AKIYAMA T: UCN-01 (7-hydroxystaurosporine) and other indolocarbazole compounds: a new generation of anti-cancer agents for the new century? Anticancer Drug Des. (2000) 15:43-52.
136. GRAVES PR, YU L, SCHWARZ JK et al.: The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem. (2000) 275:5600-5605.
137. TSE AN, SCHWARTZ GK: Potentiation of cytotoxicity of topoisomerase I poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res. (2004) 64:6635-6644.
138. HOTTE SJ, OZA A, WINQUIST EW et al.: Phase II study of topotecan (T) in combination with the novel kinase inhibitor ucUCN-01 in patients with advanced cancer. Clin. Cancer Res. (2003) 9(Suppl. 16):C80.
139. JIMENO A, RUDECK MA, PURCELL WT et al.: Phase I and pharmacokinetic study of UCN01 (U) in combination with irinotecan (I) in patients with solid tumors. Eur. J. Cancer (2004) 2(Suppl.) 8:128.
140. GANDARA DR, LARA PN, LONGMATE J et al.: The cyclin-dependent kinase (CDK) inhibitor UCN-01 plus cisplatin in advanced solid tumors: A California Cancer Consortium Phase I Trial. Proc. Am. Soc. Clin. Oncol. (2003) 22:246 (Abstract 987).
141. HAKIMIAN RR, EDELMAN MJ, BAUER K et al.: Phase I and pharmacokinetic (PK) study of the cyclin dependent kinase (CDK) inhibitor UCN-01 and carboplatin in solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:149 (Abstract 598).
142. SHAW VA, RINI BI, PARK JW et al.: A Phase II study of UCN-01 in advanced renal cell carcinoma. Proc. Am. Soc. Clin. Oncol. (2003) 22:442 (Abstract 1775).
143. KORTMANSKY JS, SAUTER N, O'REILLY E et al.: Management of hyperglycemia in patients with metastatic pancreatic cancer receiving UCN-01 and fluorouracil. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 2140.
144. SATO S, FUJITA N, TSURUO T: Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene (2002) 21:1727-1738.
145. TESTA JR, BELLACOSA A: AKT plays a central role in tumorigenesis. Proc. Natl. Acad. Sci. USA (2001) 98:10983-10985.
146. BRAZIL DP, YANG Z-Z, HEMMINGS BA: Advances in protein kinase B signalling: AKTion on multiple fronts. Trends Biochem. Sci. (2004) 29:233-242.
147. SUPURAN CT. Indisulam: an anticancer sulfonamide in clinical development. Expert Opin. Investig. Drugs (2003) 12:283-287.
148. VAN KESTEREN C, BEIJNEN JH, SCHELLENS JHM: E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer. Anti Cancer Drugs (2002) 13:989-997.
149. HADDAD RI, SHAPIRO GI, WEINSTEIN L et al.: A Phase II study of E7070 in patients with metastatic, recurrent, or refractory head and neck squamous cell carcinoma (HNSCC): Clinical activity and post-treatment modulation of Rb phosphorylation. Proc. Am. Soc. Clin. Oncol. (2003) 22:200 (Abstract 800).
150. AAMDAL S, SMYTH J, AWADA A et al.: Phase II study of E7070 in patients with metastatic melanoma (stage IV). Eur. J. Cancer (2002) 38(Suppl. 7):50.
151. DITTRICH C, GNEIST M, ZANDVLIET A et al.: Phase I and pharmacokinetic study of indisulam (E7070) in combination with carboplatin, a CESAR Central European Society for Anticancer Drug Research - EWIV report. Eur. J. Cancer (2004) 2(Suppl. 8):129.
152. OWA T, OZAWA Y, YOKOI A et al.: Identification of response marker genes of the antitumor sulfonamide indisulam (E7070). Eur. J. Cancer (2004) 2(Suppl. 8):128.
153. MISRA RN, XIAO H-Y, KIM KS et al.: N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[([5-(1,1-dimethylethyl)-2-oxazolyl] methyl)thio]-2- thiazolyl)-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent. J. Med. Chem. (2004) 47:1719-1728.
154. McCORMICK J, GADGEEL SM, HELMKE W et al.: Phase I study of BMS-387032, a cyclin dependent kinase (CDK) 2 inhibitor. Proc. Am. Soc. Clin. Oncol. (2003) 22:208 (Abstract 835).
155. BURRIS HA, LORUSSO P, JONES S et al.: Phase I trial of novel kinesin spindle protein (KSP) inhibitor SB-715992 IV days 1, 8, 15 q 28 days. Proc. Am. Soc. Clin. Oncol. (2004):Abstract 2004.
156. SHAPIRO G, LEWIS N, BAI S et al.: A Phase I study to determine the safety and pharmacokinetics (PK) of BMS-387032 with a 24-hr infusion given every three weeks in patients with metastatic refractory solid tumors. Proc. Am. Soc. Clin. Oncol. (2003) 22:199 (Abstract 799).
157. LANE ME, TEMPLE K, YU B et al.: Combined treatment with cisplatin and a novel Cdk2 specific inhibitor (BMS-387032), results in cytotoxic synergy in human colon carcinoma cells that is dependent on dose, sequence and cyclin D1 exp6ression. Proc. Amer. Assoc. Cancer Res. (2003) 44:Abstract 706.
158. WONG TW, WANG C, LEE F et al.: Identification of a biomarker of CDK2 inhibition with BMS-387032. Clin. Cancer Res. (2003) 9(Suppl. 16):C84.
159. BARR FA, SILLJE HHW, NIGG EA: Polo-like kinases and the orchestration of cell division. Nat. Rev. Mol. Cell Biol. (2004) 5:429-441.
160. WHEELER C, STEPHENS T, BYTH K et al.: Novel approaches in oncology at AstraZeneca. Eur. J. Cancer Suppl. (2003) 1(8):3-8.
161. BYTH K, GEH C, FORDER C et al.: Novel cell cycle inhibitors: characterisation in tumour cell lines and normal cycling cells. Proc. Amer. Assoc. Cancer Res. (2003) 44:Abstract 3124.
162. CAI D, BYTH K, SHAPIRO GI: A novel CDK inhibitor induces cell cycle blockade, E2F1-dependent apoptosis, and cytotoxic synergy with DNA-damaging agents. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 826.
163. ANDERSON M, BEATTIE JF, BREAULT GA et al.: Imidazo(1,2-a)pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridization. Bioorg. Med. Chem. Lett. (2003) 13:3021-3026.
164. BYTH KF, CULSHAW JD, GREEN S et al.: Imidazo(1,2-a)pyridines. Part 2: SAR and optimisation of a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2245-2248.
165. BYTH KF, COOPER N, CULSHAW JD et al.: Imidazo(1,2-b)pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:2249-2252.
166. THOMAS AP, BARTON PJ, CULSHAW JD et al.: The discovery of 4-alkoxy-2-anilino-5-cyanopyrimidines - SAR and characterization of potent and selective CDK inhibitors. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 836.
167. BYTH K, WILKINSON R, McGREGOR S et al.: Development of selective cyclin-dependent kinase inhibitors: Pharmacodynamic characterization in human tumor xenografts. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 832.
168. MAGGOS C: Schering's newco. BioCentury (2004) 12(28):A7-A9.
169. SIEMEISTER G, BRIEM H, BRUMBY T et al.: The dual-specific CDK2/VEGF-RTK inhibitor ZK-CDK potently inhibits proliferation of human tumor cells, induces apoptosis, and inhibits growth of human xenograft tumors. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 829.
170. TRAXLER P: Tyrosine kinases as targets in cancer therapy - successes and failures. Expert Opin. Ther. Targets (2003) 7:215-234.
171. SIEMEISTER G, BRIEM H, BRUMBY T et al.: Simultaneous targeting of tumor cell proliferation and tumor-induced neoangiogenesis by the novel CDK2 & VEGFRTK dual pathway inhibitor ZKCDK. Eur. J. Cancer (2004) 2(Suppl. 8):124.
172. XIAO Z, HAO Y, LIU B et al.: Indirubin and meisoindigo in the treatment of chronic myelogenous leukemia in China. Leukemia Lympboma (2002) 43:1763-1768.
173. HOESSEL R, LECLERC S, ENDICOTT JA et al.: Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell Biol. (1999) 1:60-67.
174. LECLERC S, GARNIER M, HOESSEL R et al.: Indirubins inhibit glycogen synthase kinase-3b and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease A property common to most cyclin-dependent kinase inhibitors? J. Biol. Chem. (2001) 276:251-260.
175. BAIN J, McLAUCHLAN H, ELLIOTT M et al.: The specificities of protein kinase inhibitors: an update. Biochem. J. (2003) 371:199-204.
176. VANDERWEL SN, HARVEY PJ, SHEEHAN DJ et al.: Highly selective inhibition of Cdk4 with pyrido(2,3-d)pyrimidin-7-ones. Proc. Am. Assoc. Cancer Res. (2004):Abstract 828.
177. BOOTH J, ELLIOTT W, FRY DW et al.: Inhibition of Cdk4 causes tumor regression. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 831.
178. FRY DW, HARVEY PJ, KELLER PR et al.: Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. (2004) 3:1427-1438.
179. BARVIAN M, BOSCHELLI DH, CROSSROW J et al.: Pyrido(2,3-d) pyrimidin-7-one inhibitors of cyclin-dependent kinases. J. Med. Chem. (2000) 43:4606-4616.
180. FRY DW, BEDFORD DC, HARVEY PH et al.: Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6. J. Biol. Chem. (2001) 276:16617-16623.
181. HARVEY PJ, KELLER PR, TOOGOOD PL et al.: Biological response to Cdk inhibitors as a determinant of Cdk4 versus Cdk2 selectivity. Proc. Amer. Assoc. Cancer Res. (2003) 44:(Abstract 3120).
182. EMANUEL SL, GRUNINGER R, LIN R et al.: Inhibition of human tumor xenograft growth by a novel, potent and selective CDK inhibitor. Proc. Amer. Assoc. Cancer Res. (2003) 44:(Abstract 707).
183. EMANUEL SL, RUGG C, LIN R et al.: Evaluation of the CDK inhibitor JNJ-7706621 as a targeted antitumor agent. Proc. Am. Assoc. Cancer Res. (2004) 45:(Abstract 833).
184. YIN X, FILIPOVIC Z, SMITH M et al.: Expression and phosphorylation status of retinoblastoma protein in peripheral blood mononuclear cells: Potential use as a surrogate tissue for monitoring cyclin dependent kinase inhibitors in the clinic. Proc. Am. Assoc. Cancer Res. (2004) 45:(Abstract 2612).
185. DEPINTO WE, YIN X, SMITH M et al.: The in vitro and in vivo effects of small molecule inhibitors of cyclin dependent kinase 4. Proc. Amer. Assoc. Cancer Res. (2003) 44:(Abstract 3126).
186. DERMATAKIS A, THOMPSON T, LUK K-C et al.: 4-Alkynyl oxindole inhibitors of cyclin-dependent kinase 2. Design rationale, synthesis and biochemical evaluation. Proc. Amer. Assoc. Cancer Res. (2003) 44:Abstract 3973.
187. LUK K-C, SIMCOX ME, SCHUTT A et al.: A new series of potent oxindole inhibitors of CDK2. Bioorg. Med. Chem. Lett. (2004) 14:913-917.
188. DERMATAKIS A, LUK K-C, DEPINTO W. Synthesis of potent oxindole CDK2 inhibitors. Bioorg. Med. Chem. (2003) 11:1873-1881.
189. LIU J-J, DERMATAKIS A, LUKACS C et al.: 3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors. Bioorg. Med. Client. Lett. (2003) 13:2465-2468.
190. CALIGIURI M, BOCKOVICH N, OALMANN C et al.: GPC-286199: A potent, broad spectrum inhibitor of the cyclin dependent kinases. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 830.
191. CASTEDO M, PERFETTINI J-L, ROUMIER T et al.: Cell death by mitotic catastrophe: a molecular definition. Oncogene (2004) 23:2825-2837.
192. ZHU G, CONNER SE, ZHOU X et al.: Synthesis, structure-activity relationship, and biological studies of indolocarbazoles as potent cyclin D1-CDK4 inhibitors. J. Med. Chem. (2003) 46:2027-2030.
193. ZHU G, CONNER S, ZHOU X et al.: Synthesis of quinolinyl/isoquinolinyl[a]pyrrolo (3,4-c)carbazoles as cyclin D1/CDK4 inhibitors. Bioorg. Med. Chem. Lett. (2003) 13:1231-1235.
194. ENGLER TA, FURNESS K, MALHOTRA S et al.: Novel, potent and selective cyclin D1/CDK4 inhibitors: indolo(6,7-a)pyrrolo(3,4-c)carbazoles. Bioorg. Med. Chem. Lett. (2003) 13:2261-2267.
195. HAMDOUCHI C, KEYSER H, COLLINS E et al.: The discovery of a new structural class of cyclin-dependent kinase inhibitors, aminoimidazo(1,2-a)pyridines. Mol. Cancer Ther. (2004) 3:1-9.
196. MERCURIO C, PASTORI W, CRIPPA S et al.: In vitro and in vivo characterization of the CDK2 inhibitor PHA-533533. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 824.
197. PEVARELLO P, FANCELLI D, VULPETTI A et al.: 3-Amino-pyrrolo[3,4-c] pyrazoles: A new class of CDK2 inhibitors. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 2479.
198. FANCELLI D, BERTA D, BINDI S et al.: 3-Amino-pyrrolo[3,4-c]pyrazole: Design and validation of a novel, highly versatile scaffold for kinase inhibition. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 2481.
199. PEVARELLO P, BRASCA MG, AMICI R et al.: 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. J. Med. Chem. (2004) 47:3367-3380.
200. WANG S, WOOD G, MEADES C et al.: Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-y1)pyrimidine CDK inhibitors. Bioorg. Med. Chem. Lett. (2004) 14:4237-4240.
201. GRIFFITHS G, MIDGLEY C, GRABAREK J et al.: Identification and characterization of kinase inhibitors that inhibit CDK2, CDK7 and CDK9 activities, induce p53 and result in reduced proliferation and induction of apoptosis of human tumor cells. Proc. Am. Assoc. Cancer Res. (2004) 45:Abstract 837.
202. WANG S, MEADES C, WOOD G et al.: 2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: Synthesis, SAR analysis, X-ray crystallography, and biological activity. J. Med. Chem. (2004) 47:1662-1675.
203. COATS S, PAYTON M, CHUNG G et al.: Discovery and evaluation of inhibitors of cyclin E2-CDK2 and cyclin B1-CDK1. Eur. J. Cancer (2004) 2(Suppl. 8):124.
204. WYATT PG, BERDINI V, CARR MG et al.: Identification of novel cyclin dependent kinase 1/2 inhibitors using fragment based high-throughput X-ray crystallography and structure based drug design. Eur. J. Cancer (2004) 2(Suppl. 8):38.
205. WARNER SL, BEARSS DJ, HAN H et al.: Targeting Aurora-2 kinase in cancer. Mol. Cancer Ther. (2003) 2:589-595.
206. JASCHKE B, MILZ S, VOGESER M et al.: Local cyclin-dependent kinase inhibition by flavopiridol inhibits coronary artery smooth muscle cell proliferation and migration: Implications for the applicability on drug-eluting stents to prevent neointima formation following vascular injury. FASEB J. (2004) 18:1285-1287.
207. DOERIG C: Protein kinases as targets for anti-parasitic chemotherapy. Biochim. Biophys. Acta (2004) 1697:155-168.
208. TSAI L-H, LEE M-S, CRUZ J: Cdk5, a therapeutic target for Alzheimer's disease? Biochim. Biophys. Acta (2004) 1697:137-142.
209. SMITH PD, O'HARE MJ, PARKE DS: Emerging pathogenic role for cyclin dependent kinases in neurodegeneration. Cell Cycle (2004) 3:289-291.
210. FISCHER PM: CDK versus GSK-3 inhibition: a purple haze no longer? Chem. Biol. (2003) 10:1144-1146.
211. POLYCHRONOPOULOS P, MAGIATIS P, SKALTSOUNIS A-L et al.: Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases. J. Med. Chem. (2004) 47:935-946.
212. GRIFFIN SV, PICHLER R, WADA T et al.: The role of cell cycle proteins in glomerular disease. Semin. Nephrol. (2003) 23:569-582.
213. HIROMURA K, SHANKLAND SJ: Negatively regulating the cell cycle can be positive. J. Amer. Soc. Nephrol. (2004) 15:1361-1362.
214. NELSON PJ, D'AGATI VD, GRIES J-M et al.: Amelioration of nephropathy in mice expressing HIV-1 genes by the cyclin-dependent kinase inhibitor flavopiridol. J. Antimicrob. Chemother. (2003) 51:921-929.
215. GHERARDI D, D'AGATI V, CHU T-HT et al.: Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202. J. Amer. Soc. Nephrol. (2004) 15:1212-1222.
216. HRICIK DE, CHUNG-PARK M, SEDOR JR: Glomerulonephritis. New England J. Med. (1998) 339:888-899.
217. TAM FW, SMITH J, MOREL D et al.: Development of scarring and renal failure in a rat model of crescentic glomerulonephritis. Nephrol. Dial. Transplant. (1999) 14:1658-1666.
218. SHERYANNA AM, SMITH J, BARNETT A et al.: Renal Week 2004 (2004):Abstract SU-P0715.
219. BALOMENOS D, MARTIN-CABALLERO J, GARCIA MI et al.: The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat. Med. (2000) 6:171-176.
220. ZOJA C, CONTI S, CORNA D et al.: Renal Week 2004 (2004): (Abstract SU-P0707).
221. SADAIE MR, MAYNER R, DONIGER J: A novel approach to develop anti-HIV drugs: adapting non-nucleoside anticancer chemotherapeutics. Antivir. Res. (2004) 61:1-18.
222. SCHANG LM: Effects of pharmacological cyclin-dependent kinase inhibitors on viral transcription and replication. Biochim. Biophys. Acta (2004) 1697:197-209.
223. HESSELGESSER J, GIBBS CS, SHIBATA R: 11th Conference on Retroviruses and Opportunistic Infections (2004): (Abstract 546).
224. CHIU Y-L, CAO H, JACQUE J-M et al.: Inhibition of human immunodeficiency virus Type 1 replication by RNA interference directed against human transcription elongation factor P-TEFb (CDK9/CyclinT1). J. Virol. (2004) 78:2517-2529.
225. BECKER F, MURTHI K, SMITH C et al.: A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. Chem. Biol. (2004) 11:211-223.
226. GRAY NS, WODICKA L, THUNISSEN A-MWH et al.: Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. Science (1998) 281:533-538.
227. ZHANG G-J, SAFRAN M, WEI W et al.: Bioluminescent imaging of Cdk2 inhibition in vivo. Nat. Med. (2004) 10:643-648.
228. BROWN NR, NOBLE ME, ENDICOTT JA et al.: The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. CeIl Biol. (1999) 1:438-443.